Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy
Anne G. Semb, MD, PhD*,
Sanne van Wissen, MD ,
Thor Ueland, BS ,
Tineke Smilde, MD, PhD,
Torgun Waehre, MD,
Mieke D. Tripp, MD, PhD ,
Stig S. Frøland, MD, PhD||,
John J. P. Kastelein, MD, PhD,
Lars Gullestad, MD, PhD¶,
Terje R. Pedersen, MD, PhD*,
P.ål Aukrust, MD, PhD||,* and
Anton F. H. Stalenhoef, MD, PhD
* Cardiologic Department, Aker Hospital, Oslo, Norway
Research Institute for Internal Medicine, Oslo, Norway
|| Section of Clinical Immunology and Infectious Diseases, Rikshospitalet, Oslo, Norway
¶ Medical Department, Baerum Hospital, Baerum, Norway
Academic Medical Center, Amsterdam, The Netherlands
Department of Medicine, University Medical Center, Nijmegen, The Netherlands
View larger version (18K):
[in a new window]
|
Figure 1 Serum levels of soluble CD40 ligand (sCD40L) in 110 patients with familial hypercholesterolemia (FH) compared with 20 gender- and age-matched healthy controls (CTR). Data are given as median and 25th to 75th percentiles. *p < 0.001 versus controls.
|
|
View larger version (23K):
[in a new window]
|
Figure 2 Serum levels of soluble CD40 ligand (sCD40L) in 110 patients with familial hypercholesterolemia receiving atorvastatin 80 mg (n = 57) or simvastatin 40 mg (n = 53) daily for two years (yr). Data are given as median and 25th to 75th percentiles. Open bar = atorvastatin; hatched bar = simvastatin. *p < 0.01; **p < 0.001 versus baseline.
|
|
|
